Why Is VIR BIOTECHNOLOGY IN (VIR) Stock Down Today?

Vir Biotechnology (VIR) shares fell 18.28% to $9.90, driven by the pricing of a $150 million equity offering. The company priced 15 million shares of common stock at $10 per share, a discount to the prior close. Leerink, Morgan Stanley, and Evercore ISI led the underwritten public offering.

What Happened

The stock opened at $10.46, marking a 13.7% gap down from the previous close of $12.12. The session high was $10.73 at 8:30 AM ET, while the low reached $9.87 at 10:05 AM ET. The move follows the announcement of the proposed public offering, which was subsequently priced at $10.00 per share for gross proceeds of $150 million. This equity raise is significant for a company with a market capitalization of $2.2 billion.

What The Data Shows

Trading volume reached 7.6 million shares, which is 4.0 times the three-month daily average. The stock printed 10 fresh 52-week lows on November 13, 2026. Fundamentals show the company is unprofitable with a trailing twelve-month EPS of -1.18 and a net margin of -61.0%, though revenue grew 1696.0% over the same period. The 52-week range is $5.32 to $14.38. Over the last eight sessions prior to the drop, the stock had moved up 8.0% from $11.22 to $12.12. Recent insider activity includes a sale by EVP, GC, and Corporate Secretary Vanina De Verneuil on November 2, 2026. Total insider sales in the last 90 days amounted to $42,000, with no buys recorded.

What To Watch

Coverage from seven sources in the last 36 hours highlights the market reaction to the capital raise. Investors will monitor how the stock stabilizes following the dilution event and the subsequent use of the $150 million in proceeds.